Modulation of Heme Oxygenase 1 by Nizatidine and Lisinopril in Healthy Subjects

Completed · Phase 1 · Has a placebo group

Conditions studied: Gastroparesis

In brief

To assess if oral nizatidine or lisinopril alone and in combination will increase heme oxygenase 1 (HO-1) protein concentration and activity compared to placebo in healthy subjects.

Key facts

Study ID

NCT02232308

Run by

Adil Bharucha

People needed

24

Starts

2014-07-01

Expected to finish

2014-09-01

Last updated by the study team

2015-04-30

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy subjects without clinical evidence of significant cardiovascular, gastrointestinal, hematological, neurological, psychiatric or other disease that may interfere with the objectives of the study and/or pose safety concerns
• Normal serum potassium and estimated glomerular filtration rate (eGFR) > 60 ml/minute
• Baseline systolic BP ≥ 110 mmHg
• No known hypersensitivity to lisinopril or nizatidine
• Able to provide written informed consent before participating in the study
• Able to communicate adequately with the investigator and to comply with the requirements for the entire study.

You may not qualify if…

• Pregnant
• Breast feeding
• Current smoker
• Symptoms of functional GI disorder as assessed by a validated questionnaire
• Previous history of peptic ulcer disease.

Where it is running

• Mayo Clinic in Rochester — Rochester, Minnesota, United States
• Mayo Clinic — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.